2023 ID-IRI Activities: Information Overview

Dear ID-IRI Members,

We are pleased to share an overview of the 2023 activities conducted by ID-IRI. Below, you’ll find a list of projects recently published or currently underway:

Published ID-IRI Projects in 2023:

  1. Investigation on clinical outcomes and factors impacting mortality in intensive care unit patients with COVID-19-associated Candidemia. (Mycoses, In press)
  2. Prospective analysis of febrile neutropenia patients with bacteraemia: The findings from the ID-IRI study. (International Journal of Antimicrobial Agents 2023; 7;62(3):106919)
  3. Clinicopathological profile of peritoneal tuberculosis and the introduction of a novel scoring model for predicting mortality: An international ID-IRI study. (European Journal of Clinical Microbiology and Infectious Diseases 2023;42(8):981-992)
  4. Investigating infectious causes of fever of unknown origin in developing countries: An international ID-IRI Study. (Journal of Intensive Medicine, In press)
  5. Examination of Classical Fever of Unknown Origin across 21 countries with varying economic development: An International ID-IRI Study. (European Journal of Clinical Microbiology and Infectious Diseases 2023;42(4):387-398)
  6. Analysis of features related to Mpox Infection based on data submitted to the ID-IRI network. (New Microbes and New Infections 2023;53:101154)

Ongoing ID-IRI Projects:

  1. Prospective observational international study on surgical site infections after cardiac surgery. This project is nearing completion and will soon be distributed to participants.
  2. Investigations on COVID-19-associated Mucormycosis Paper has been submitted elsewhere.
  3. COVID-19-associated Aspergillosis. Paper has been submitted elsewhere.
  4. Research on Primary Brain Abscesses – Data analysis is ongoing.
  5. Collection of data on PCP pneumonia continues.
  6. Ongoing data collection for the Stenotrophomonas Study.

Thank you for your ongoing dedication and contributions to these crucial endeavors. Best wishes

Leave a comment